SERMORELIN

Sermorelin

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human growth hormone-releasing hormone, GHRH(1-29)-NH₂. That short N-terminal fragment is the smallest portion of the native 44-residue hormone that retains full activity at the GHRH receptor, which is why it has been a standard reference ligand in pituitary and neuroendocrine research for decades.

Product Specifications

• Product: Sermorelin
• Amount: See available options above
• Form: Lyophilized powder
• Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
• Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
• Ships from: United States, 2-day UPS

Chemical Profile

• Compound class: Synthetic 29-amino-acid peptide, GHRH(1-29) amide
• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂
• Molecular formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular weight: 3357.9 g/mol
• CAS number: 86168-78-7

What researchers study

The GHRH receptor is a class B G protein-coupled receptor expressed mainly on somatotroph cells of the anterior pituitary. When GHRH or GHRH(1-29) binds, the receptor signals through G_s and adenylate cyclase, raising intracellular cAMP. Laboratories use Sermorelin to study that pathway: receptor binding and activation, cAMP signaling in pituitary cell and membrane preparations, structure-activity relationships across the peptide sequence, and the regulation of somatotroph cells.

Early structure-activity work in rat anterior pituitary membranes showed how single substitutions near the N-terminus change the peptide from an activator into an antagonist, which made GHRH(1-29) a useful scaffold for designing receptor probes. The receptor itself was cloned in 1992, giving researchers expression systems for studying GHRH signaling outside the pituitary.

Background & regulatory status

A prescription sermorelin acetate product was previously approved in the United States. It was discontinued in 2008, and FDA later determined it was not withdrawn for reasons of safety or effectiveness. The material sold here is a research reagent only and is not an approved drug.

Quality & Documentation

Every batch of Sermorelin is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.

Research overview

For a longer look at Sermorelin, covering where it came from, what cell and animal studies have measured, and what the evidence does not show, read our Sermorelin research overview. It is written as background reading, and every study it cites is linked to PubMed.

Selected literature

• Ling N, et al. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci USA. 1984;81:4302-4306. PMID 6431406
• Robberecht P, et al. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF). Endocrinology. 1985;117:1759-1764. PMID 2994998
• Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. PMID 1333056
• Mayo KE, et al. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res. 2000;55:237-266. PMID 11036940
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID 18031173

Research Use Only

This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.